L-T3 pharmaceutical equivalency, Part 2: New thyroid science

What does NEW thyroid science have to say on the topic of thyroid pharmaceutical equivalency? How many micrograms of L-T3 Liothyronine (i.e. Cytomel) are equivalent to L-T4 Levothyroxine (i.e. Synthroid)? Thyroid hormone pharmaceutical monographs currently provide very rigid and low-ratio equivalency statements: ERFA Canada says "Desiccated thyroid 60 mg is usually considered equivalent to ... …

Continue reading L-T3 pharmaceutical equivalency, Part 2: New thyroid science

No, 25 mcg of L-T3 Liothyronine isn’t equivalent to 100 mcg L-T4

In thyroid therapy, how many micrograms of Cytomel (T3) are equivalent to how many micrograms of Synthroid (T4)? Equivalency statements in the product monographs for Pfizer Canada's Cytomel and for ERFA Canada's "Thyroid" (NDT brand) claim that a 25 mcg dose of Liothyronine sodium (L-T3) is "considered equivalent" to 100 mcg / μg (0.1 mg) …

Continue reading No, 25 mcg of L-T3 Liothyronine isn’t equivalent to 100 mcg L-T4

Global thyroid pharma economics: T3 meds

Here's an update on prices in some locations of the world, and Canada, for synthetic T3 medication, known by the chemical name liothyroinine. UNITED KINGDOM & GREECE A Daily Mail article published May 27, 2019 reported the prices for T3 / Liothyronine pills in the UK over time, and today in Greece: 20-25 mcg / …

Continue reading Global thyroid pharma economics: T3 meds

2014 ATA Therapy guidelines: 3. Desiccated thyroid

If we want to disagree with the American Thyroid Association's prejudice against animal sources of thyroid hormone, we should to at least prove we're trying to listen to them. Then we should fairly point out what they didn't say, what truths they would rather not admit, and where they are being unfair or inconsistent. This post …

Continue reading 2014 ATA Therapy guidelines: 3. Desiccated thyroid

2014 ATA thyroid therapy guidelines: 1. Levothyroxine

In this series of posts, I paraphrase a 2014 thyroid therapy guidelines document in a way that even the brain-fogged hypothyroid patient can understand more quickly and easily than reading the original version. MY SUMMARY'S AIMS AND METHODS Every thyroid patient understand the basics about what is being said about their therapy by the American …

Continue reading 2014 ATA thyroid therapy guidelines: 1. Levothyroxine

Pharma prejudice refuses a paradigm shift in thyroid therapy

This post engages in a moral argument, not a scientific one. Thyroid pharmaceutical prejudice is part of a paradigm that is refusing to shift. We need to keep asking key questions and fight together for this shift. Look around you today. Thyroid guidelines and health care systems currently treat all thyroid patients as one undifferentiated …

Continue reading Pharma prejudice refuses a paradigm shift in thyroid therapy

Thyroid pharma: Bioidentical yet harmful?

Any fair criticism of a medication's potential for harm or benefit should first examine the properties of the medication and how it interacts with the human body in general. Next, we should distinguish the content of a pharmaceutical tool from its use (dosing adjustments, circumstances). Then finally, we should consider this: The therapy has to …

Continue reading Thyroid pharma: Bioidentical yet harmful?